Cell Therapeutics (CTIC) Posts Q3 Loss of 16c/Share; Resubmits Pixantrone NDA to FDA
Cell Therapeutic
Cell Therapeutics also resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma for patients who have failed two or more prior lines of therapy.
s Inc. (NASDAQ: CTIC) reported Q3 loss of ($0.16), $0.07 worse than the analyst estimate of ($0.09).
Cell Therapeutics also resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma for patients who have failed two or more prior lines of therapy.